JP2005526087A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526087A5
JP2005526087A5 JP2003576401A JP2003576401A JP2005526087A5 JP 2005526087 A5 JP2005526087 A5 JP 2005526087A5 JP 2003576401 A JP2003576401 A JP 2003576401A JP 2003576401 A JP2003576401 A JP 2003576401A JP 2005526087 A5 JP2005526087 A5 JP 2005526087A5
Authority
JP
Japan
Prior art keywords
rhinitis
asthma
chronic
allergic
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526087A (ja
Filing date
Publication date
Priority claimed from SE0200844A external-priority patent/SE0200844D0/xx
Application filed filed Critical
Publication of JP2005526087A publication Critical patent/JP2005526087A/ja
Publication of JP2005526087A5 publication Critical patent/JP2005526087A5/ja
Pending legal-status Critical Current

Links

JP2003576401A 2002-03-19 2003-03-17 ケモカインレセプター活性モジュレーターとして有用なピペリジン誘導体 Pending JP2005526087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200844A SE0200844D0 (sv) 2002-03-19 2002-03-19 Chemical compounds
PCT/SE2003/000443 WO2003078395A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
JP2005526087A JP2005526087A (ja) 2005-09-02
JP2005526087A5 true JP2005526087A5 (enExample) 2006-04-20

Family

ID=20287326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576401A Pending JP2005526087A (ja) 2002-03-19 2003-03-17 ケモカインレセプター活性モジュレーターとして有用なピペリジン誘導体

Country Status (6)

Country Link
US (2) US7517989B2 (enExample)
EP (1) EP1487793A1 (enExample)
JP (1) JP2005526087A (enExample)
AU (1) AU2003212770A1 (enExample)
SE (1) SE0200844D0 (enExample)
WO (1) WO2003078395A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
MXPA03011722A (es) 2001-07-02 2004-03-19 Aztrazeneca Ab Derivados de piperidina utiles como moduladores de actividad de quimiocina.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) * 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
AU2003209204A1 (en) * 2002-01-10 2003-07-30 University Of Washington Hydrogels formed by non-covalent linkages
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
US20080200505A1 (en) * 2005-05-27 2008-08-21 Astrazeneca Ab Piperidines for the Treatment of Chemokine Mediated Diseases
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8610368B2 (en) 2009-12-21 2013-12-17 Top Victory Investments Ltd. Serial-type light-emitting diode (LED) device
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (enExample) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
EP0612313A1 (en) 1991-11-14 1994-08-31 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
WO1996041631A1 (en) * 1995-06-09 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
NZ333513A (en) 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CN1155574C (zh) 1996-08-15 2004-06-30 先灵公司 醚毒蕈碱性拮抗剂
DK0927192T3 (da) 1996-09-10 2004-09-13 Boehringer Ingelheim Pharma Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
WO1999038514A1 (en) 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
DE69922186T2 (de) 1998-04-28 2005-05-04 Dainippon Pharmaceutical Co., Ltd. 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
ATE272632T1 (de) 1998-06-30 2004-08-15 Schering Corp Muskarin-rezeptor antagonisten
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
WO2000032590A1 (en) 1998-11-25 2000-06-08 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
WO2000035877A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
KR100439357B1 (ko) 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002018335A1 (en) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Cyclic amine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
ES2342942T3 (es) 2001-03-29 2010-07-19 Schering Corporation Antagonistas de ccr5 utiles para el tratamiento del sida.
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
MXPA03011722A (es) 2001-07-02 2004-03-19 Aztrazeneca Ab Derivados de piperidina utiles como moduladores de actividad de quimiocina.
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
MXPA05013474A (es) 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
SE0400925D0 (sv) 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
TW200722419A (en) 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
US20080200505A1 (en) 2005-05-27 2008-08-21 Astrazeneca Ab Piperidines for the Treatment of Chemokine Mediated Diseases
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体

Similar Documents

Publication Publication Date Title
JP2005526087A5 (enExample)
JP5225085B2 (ja) 新規なキャップ化ピラジノイルグアニジンナトリウムチャネル遮断薬
RU2382783C2 (ru) Органические соединения
ES2399179T3 (es) Tratamiento de enfermedad respiratoria
US20110003858A1 (en) Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
RU2008140910A (ru) Новые пиперидины в качестве модуляторов хемокинов (ccr)
US20060014780A1 (en) Nicotinamide derivatives useful as PDE4 inhibitors
JP2008509187A5 (enExample)
US20120196854A1 (en) Pharmaceutical composition comprising aromatic heterocyclic compound
NO20024708L (no) Behandling av respiratoriske sykdommer
TW200307545A (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
JP2014521724A (ja) 一過性受容器電位イオンチャネルｔｒｐａ１の阻害
TW200845998A (en) Heterocyclic compounds useful in treating diseases and conditions
NZ591914A (en) Naphthylacetic acids
JP2008525397A5 (enExample)
JP2017524674A (ja) 慢性閉塞性気道疾患の治療のための６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−化合物
HRP20191339T1 (hr) Novi anelirani fenoksiacetamidi
US20060069124A1 (en) Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
CA2667041A1 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
CA2705729A1 (en) Pyrazole derivatives as 5-lo inhibitors
US6756392B2 (en) Nicotinamide derivatives useful as PDE4 inhibitors
US20030191158A1 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
JP2006504768A (ja) 四級アンモニウム化合物
JP2008524158A5 (enExample)